News
GKOS
--
0.00%
--
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Zacks · 6d ago
--Stifel Nicolaus Adjusts Price Target for Glaukos to $40 From $55, Maintains Hold Rating
MT Newswires · 6d ago
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:45
BRIEF-Glaukos Corporation Announces First Quarter 2022 Financial Results
reuters.com · 05/04 21:23
Glaukos Q1 Adj. EPS $(0.38) Beats $(0.50) Estimate, Sales $67.70M Beat $60.85M Estimate
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.50) by 24 percent. This is a 80.95 percent decrease over losses of $(0.21) per share from the same
Benzinga · 05/04 20:18
Glaukos Non-GAAP EPS of -$0.38 beats by $0.13, revenue of $67.7M beats by $6.85M
Glaukos press release (NYSE:GKOS): Q1 Non-GAAP EPS of -$0.38 beats by $0.13. Revenue of $67.7M (-0.4% Y/Y) beats by $6.85M.
Seekingalpha · 05/04 20:16
-- Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Revenue $67.7M, vs. Street Est of $60.9M
MT Newswires · 05/04 16:46
-- Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Loss $-0.38, vs. Street Est of $-0.51
MT Newswires · 05/04 16:41
Glaukos (NYSE:GKOS) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 05/03 15:13
Intuitive Surgical sheds over 10% most in over two years despite earnings beat
The shares of Intuitive Surgical (NASDAQ:ISRG) have recorded the worst intraday decline since March 2020 on Friday despite better than expected financials reported by the maker of robotic surgical systems for
Seekingalpha · 04/22 16:58
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
SAN CLEMENTE, Calif., April 21, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its t...
Business Wire · 04/21 11:00
Glaukos Announces the Release of its 2021 Sustainability Report
SAN CLEMENTE, Calif., April 20, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it ha...
Business Wire · 04/20 11:00
Johnson & Johnson’s MedTech performance rallies industry
MedTech stocks are trading sharply higher on Tuesday after the industry bellwether Johnson & Johnson (JNJ) reported better than expected 1Q 2022 sales for its MedTech segment. The iShares U.S. Medical
Seekingalpha · 04/19 17:21
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Zacks · 03/30 15:33
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
Sight Sciences Inc (NASDAQ: SGHT) has 
Benzinga · 03/25 11:08
Glaukos begins phase 2 program for 3rd gen iLink therapy to treat thinning of cornea
Glaukos (NYSE:GKOS) said it began a phase 2 program for its third generation iLink therapy to treat keratoconus, a type of eye disorder. Keratoconus occurs when the cornea thins and gradually bulges
Seekingalpha · 03/14 13:47
BRIEF-Glaukos Announces Commencement Of Phase 2 Corneal Health Clinical Program For Third-Generation Ilink Therapy
reuters.com · 03/14 11:10
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
SAN CLEMENTE, Calif., March 14, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it ha...
Business Wire · 03/14 11:00
Glaukos Says It Has Started Phase 2 Clinical Program for Eye Disease Treatment; Shares Rise Pre-Bell
MT Newswires · 03/14 09:04
Glaukos Corporation (NYSE:GKOS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Glaukos Corporation ( NYSE:GKOS ) shareholders are probably feeling a little disappointed, since its shares fell 2.5...
Simply Wall St. · 02/24 09:41
Webull provides a variety of real-time GKOS stock news. You can receive the latest news about Glaukos Corp through multiple platforms. This information may help you make smarter investment decisions.
About GKOS
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to the traditional glaucoma treatment paradigm. It offers bio-activated pharmaceutical therapy for the treatment of corneal disorder and keratoconus. It is also developing a pipeline of surgical devices, sustained pharmaceutical therapies, implantable biosensors intended to treat glaucoma progression, corneal disorders such as keratoconus, dry eye, refractive vision correction, retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.